No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study

BACKGROUND: Currently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally, causing an unprecedented pandemic. However, there is no specific antiviral therapy for coronavirus disease 2019 (COVID-19). We conducted a clinical trial to compare the effectiveness of three ant...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Front Pharmacol
Prif Awduron: Huang, Yin-Qiu, Tang, Sheng-Quan, Xu, Xiao-Lei, Zeng, Yan-Ming, He, Xiao-Qing, Li, Yao, Harypursat, Vijay, Lu, Yan-Qiu, Wan, Yan, Zhang, Lu, Sun, Qiang-Zhong, Sun, Nan-Nan, Wang, Gui-Xue, Yang, Zhong-Ping, Chen, Yao-Kai
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2020
Pynciau:
Pharmacology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7378850/
https://ncbi.nlm.nih.gov/pubmed/32765274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.01071
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg